FY2029 Earnings Estimate for STOK Issued By Leerink Partnrs

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Leerink Partnrs raised their FY2029 EPS estimates for shares of Stoke Therapeutics in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $0.60 per share for the year, up from their previous estimate of $0.55. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

A number of other research firms also recently commented on STOK. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $24.67.

Stoke Therapeutics Trading Up 12.7 %

Shares of NASDAQ:STOK traded up $0.98 during midday trading on Wednesday, hitting $8.67. The stock had a trading volume of 944,345 shares, compared to its average volume of 713,781. The company has a market capitalization of $468.86 million, a PE ratio of -4.13 and a beta of 1.09. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $17.58. The stock has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $10.35.

Insider Buying and Selling

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. GAMMA Investing LLC lifted its position in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the 4th quarter worth $63,000. Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics during the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in Stoke Therapeutics in the 4th quarter valued at $124,000. Finally, Tower Research Capital LLC TRC raised its position in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after purchasing an additional 4,918 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.